Recreational drug use, while often associated with cardiovascular and neurological harm, carries substantial risks for respiratory health that are frequently underestimated. Inhaled substances such as cannabis, cocaine, heroin, and synthetic compounds can cause direct injury to the airway epithelium, impair mucociliary clearance, and increase susceptibility to infections. Smoking-related practices, including vaping, introduce toxins and irritants that promote chronic inflammation and may accelerate lung aging. Intravenous drugs also pose indirect risks through immune suppression and increased vulnerability to respiratory infections like pneumonia or tuberculosis. Acute complications, such as bronchospasm or aspiration, further highlight the dangers associated with recreational drug use.
Addressing recreational drug–related respiratory risks requires a balanced approach that combines harm reduction with education and clinical support. Screening for respiratory symptoms in individuals with a history of substance use enables early diagnosis of underlying damage. Pulmonary rehabilitation, smoking cessation programs, and pharmacological interventions can help mitigate long-term consequences. Public health campaigns play an important role in raising awareness about the respiratory hazards of drug use, particularly among youth populations. Collaboration between addiction specialists, pulmonologists, and mental health providers fosters integrated care tailored to individual needs. By tackling both the behavioral and physiological aspects of substance use, strategies can significantly reduce recreational drug–related respiratory risks and improve overall health outcomes.
Title : Global warming and increasing respiratory illnesses
Yazdan Mirzanejad, University of British Columbia, Canada
Title :
Saurabh Chattopadhyay, University of Kentucky, United States
Title : Risk factors for mycobacterium avium complex infections in patients with chronic obstructive pulmonary disease
Alizaman Sadigov, Medical University, United States
Title : Managing integration and interoperability in transformed pulmonology, respiratory medicine and lung health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Oncology (PPO) to be set up via precision oncology strategy for cancer care team: Developing targeted lung cancer therapy and advancing personalized cancer care
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Advancements in pulmonology and respiratory care through the view of Personalized and Precision Medicine (PPM) and biodesign-driven translational applications
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation